- Dr. Anderson joins growing leadership team following successful funding round in early Summer 2022 to continue advancement of 3DNA® Platform
- Brings more than 20 years of scientific expertise in biotechnology and academia from target identification through post IND drug development in gene therapy field
PHILADELPHIA, Pa., September 28, 2022--(BUSINESS WIRE)--Code Biotherapeutics, Inc. (Code Bio), a biotechnology company pioneering targeted non-viral delivery of genetic medicines, today announces the appointment of David Anderson, PhD, as Chief Scientific Officer.
"I am thrilled to welcome Dave to the team at this exciting stage of the company’s growth," said Brian P. McVeigh, Code Bio Co-Founder, Chairman, and Chief Executive Officer. "Dave’s leadership and his extensive experience of successfully progressing multiple gene therapy programs from discovery through preclinical development will have a significant impact on the advancement of our growing pipeline of potentially transformative genetic medicines. I look forward to partnering with him to deliver on our promise to treat the untreatable and cure the incurable."
Dr. Anderson will be responsible for guiding the long-term vision for research and discovery and for driving Code Bio’s overall scientific strategy in Duchenne Muscular Dystrophy (DMD), Type 1 Diabetes (T1D), and other serious diseases. He will lead efforts across research, discovery, translational medicine, regulatory strategy, and early development.
Dr. Anderson joins Code Bio from SwanBio Therapeutics where he served as Senior Vice President, Research directing translation of genetic therapies in development for the treatment of rare neurological diseases of the spinal cord. Prior to his role at SwanBio, Dr. Anderson directed all preclinical research for the treatment of neurological diseases at Spark Therapeutics, Inc., where he oversaw development and growth of the central nervous system portfolio and team during his tenure.
"Genetic medicine has transformed the way scientists and drug developers research and discover therapies, offering hope where before there was none," said David Anderson, PhD. "I am excited to bring my years of experience in research, discovery and development to Code Bio to help advance their platform and pipeline, while contributing to the proven leadership of the team."
Beyond his experience with SwanBio and Spark, Dr. Anderson also co-founded two early-stage biotechnology companies and previously served as faculty at Thomas Jefferson University. His expertise includes all aspects of experimental design and management with significant experience in molecular discovery and translation of basic research into preclinical animal models to support drug development.
Dr. Anderson received a PhD in Molecular and Cell Biology from Thomas Jefferson University in 2005 and a B.Sc./Hons in Biomedical Sciences from Sheffield Hallam University in 1996.
About Code Biotherapeutics, Inc.
Headquartered in Greater Philadelphia, Code Bio is a biotechnology company pioneering the development of genetic medicines to treat and potentially cure serious and life-threatening genetic diseases. By leveraging its novel non-viral multivalent synthetic DNA delivery platform, 3DNA®, Code Bio’s approach can overcome multiple challenges inherent with viral-based delivery approaches, including immunogenicity, size and delivery limitations, inability to re-dose and manufacturing complexity. The company is advancing an internal pipeline of therapies focused on serious and life-threatening diseases while also developing multiple collaborative partnerships to take forward additional programs in both rare and prevalent diseases. For more information, visit www.codebiotx.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220928005248/en/
Code Bio Media:
Sam Brown Inc. Healthcare Communications